Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Kryza

Showing results (61-70 of 64) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 64 results.
EMBO Molecular Medicine|March 6, 2023
From netrin-1-targeted SPECT/CT to internal radiotherapy for management of advanced solid tumorsDavid Kryza, Jennifer Wischhusen, Mathieu Richaud, et al.
BMC Cancer|June 10, 2018
A first-in-human study investigating biodistribution, safety and recommended dose of a new radiolabeled MAb targeting FZD10 in metastatic synovial sarcoma patientsAnne-Laure Giraudet, Philippe Alexandre Cassier, Chicaco Iwao-Fukukawa, et al.
Advanced Materials (Deerfield Beach, Fla.)|December 17, 2023
Subcutaneous Administration of a Zwitterionic Chitosan-Based Hydrogel for Controlled Spatiotemporal Release of Monoclonal AntibodiesThomas Gréa, Guillaume Jacquot, Arthur Durand, et al.
European Urology Oncology|April 25, 2024
Activity of Lutetium-177 Prostate-specific Membrane Antigen and Determinants of Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Cabazitaxel: The PACAP StudyRonan Flippot, Tugce Telli, Maud Velev, et al.
Pageof 7

Showing results (61-70 of 64) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 64 results.
EMBO Molecular Medicine|March 6, 2023
From netrin-1-targeted SPECT/CT to internal radiotherapy for management of advanced solid tumorsDavid Kryza, Jennifer Wischhusen, Mathieu Richaud, et al.
BMC Cancer|June 10, 2018
A first-in-human study investigating biodistribution, safety and recommended dose of a new radiolabeled MAb targeting FZD10 in metastatic synovial sarcoma patientsAnne-Laure Giraudet, Philippe Alexandre Cassier, Chicaco Iwao-Fukukawa, et al.
Advanced Materials (Deerfield Beach, Fla.)|December 17, 2023
Subcutaneous Administration of a Zwitterionic Chitosan-Based Hydrogel for Controlled Spatiotemporal Release of Monoclonal AntibodiesThomas Gréa, Guillaume Jacquot, Arthur Durand, et al.
European Urology Oncology|April 25, 2024
Activity of Lutetium-177 Prostate-specific Membrane Antigen and Determinants of Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Cabazitaxel: The PACAP StudyRonan Flippot, Tugce Telli, Maud Velev, et al.
Pageof 7